QIAGEN: Temporary CEO

After the departure of Peer Schatz, Thierry Bernard is taking over as interim Chief Executive Officer at QIAGEN while the molecular diagnostics company is looking for a permanent head.

Bernard, who joined QIAGEN in 2015, is Senior Vice President and head of the Molecular Diagnostics Business Area at QIAGEN. Previously, je worked at bioMérieux, where he served in roles of increasing responsibility for 15 years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMérieux, he served in management roles in multiple international environments. Bernard is a member of the Boards of Directors of three privately held U.S. companies, First Light Biosciences, HepatoChem and more recently, Daktari Diagnostics, where he also served as CEO. He has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics and the College of Europe and is a member of French Foreign Trade Advisors.

Erstwhile CEO Schatz has been with QIAGEN for 27 years and CEO of the company since 1993. He will remain with the company as Special Advisor to the Supervisory Board.